Positive
●
CNBC
●
2 months ago
The Food and Drug Administration approved a once-daily HIV pill from Gilead that could help simplify care for some patients whose virus is already under control but who remain on complicated treatment regimens. The tablet combines bictegravir, the backbone of Gilead's blockbuster HIV pill Biktarvy, with lenacapavir, a centerpiece of the company's long-term strategy for HIV treatment and prevent...